TWIST1: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: TWIST1

NCBI ID: G7291

TWIST1

TWIST1: A Potential Drug Target Or Biomarker for Various Diseases

TWIST1 (Twist-related protein 1 (isoform X1)) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the Twist family of proteins, which are known for their role in cell-cell adhesion and the regulation of cell growth and differentiation.

Recent studies have identified TWIST1 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because TWIST1 has been shown to play a role in the development and progression of these conditions, and may be a useful target for therapies that can inhibit its activity.

One of the key mechanisms by which TWIST1 promotes cancer growth is its role in cell-cell adhesion. Cancer cells often undergo a process called \"cell-cell adhesion,\" which allows them to stick together and form tumors. TWIST1 has been shown to be involved in this process, and may be a useful target for cancer therapies that can disrupt this activity.

In addition to its role in cell-cell adhesion, TWIST1 has also been shown to contribute to the development and progression of neurodegenerative diseases. These conditions, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. TWIST1 has been shown to be involved in the regulation of neurotransmitter release and cell survival, and may be a useful target for therapies that can target its activity.

Another potential application of TWIST1 as a drug target is its role in the regulation of cell growth and differentiation. Many diseases, including cancer, are characterized by the uncontrolled growth and proliferation of cells. TWIST1 has been shown to play a role in the regulation of cell growth and differentiation, and may be a useful target for therapies that can disrupt its activity.

In addition to its potential as a drug target, TWIST1 has also been identified as a potential biomarker for a variety of diseases. This is because its expression is often increased in the brains and other tissues of individuals with certain diseases, such as cancer and neurodegenerative diseases. This may make TWIST1 an attractive target for biomarkers that can be used to diagnose and monitor these conditions.

Overall, TWIST1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its role in cell-cell adhesion, neurotransmission, and cell growth and differentiation, as well as its potential as a biomarker, make it an attractive target for further research and development. As research continues to progress, it is likely that TWIST1 will emerge as a promising new therapeutic target for a variety of diseases.

Protein Name: Twist Family BHLH Transcription Factor 1

Functions: Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of pro-inflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-BMAL1 heterodimer (By similarity)

The "TWIST1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TWIST1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets